Related Experiment Video
Updated: Jul 1, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Policy Brief - What's in a Name? A Search for Alternatives to "VSL"
Nathalie B Simon1,2,3,4,5, Chris Dockins1, Kelly B Maguire3
1National Center for Environmental Economics; USEPA.
None:
Benefit-cost analyses of environmental, health, and safety regulations often rely on an estimate of the value of statistical life (VSL) to calculate the aggregate benefits of reducing human mortality risk. The VSL represents the marginal rate of substitution between mortality risk and money. Although this concept is well-understood by economists, it is viewed by many non-economists as confusing technical jargon that borders on the immoral. Based on focus groups and a quantitative ranking exercise, this article describes a systematic approach for identifying and testing alternatives to the VSL terminology, with the goal of identifying an alternative term that more clearly communicates the VSL concept to a broad audience.
Related Concept Videos
Drug Nomenclature
Bioequivalence studies: Biowaivers
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

